Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434986 | 0.83 | PDF (0.38) | MMP1MMP2MMP3HDAC2SMN1; SMN2 | |
| SCHEMBL13500186 | 0.82 | MMP1 (0.44) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL13435005 | 0.79 | MMP2 (0.43) | MMP1MMP2MMP3MMP7HDAC2 | |
| SCHEMBL13435012 | 0.79 | CTSK (0.38) | HDAC2 | |
| SCHEMBL13499678 | 0.79 | TSHR (0.41) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL13461531 | 0.79 | MMP1 (0.34) | MMP1MMP2MMP3MMP7SMN1; SMN2 | |
| SCHEMBL13575213 | 0.76 | CA1 (0.45) | MMP1MMP2MMP3HDAC2POLB | |
| SCHEMBL13434996 | 0.76 | CA1 (0.45) | MMP1MMP2MMP3HDAC2POLB | |
| SCHEMBL13434995 | 0.76 | GRIK1 (0.34) | MMP1MMP2MMP3MMP7HDAC2 | |
| SCHEMBL12040054 | 0.75 | CA1 (0.42) | MMP2MMP3HDAC2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7498324-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | MMP1 2106/4885MMP2 1029/4885MMP3 2663/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | MMP1 2106/4885MMP2 1029/4885MMP3 2663/4885 |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | MMP1 2106/4885MMP2 1029/4885MMP3 2663/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | MMP1 1976/4885MMP2 957/4885MMP3 2583/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | MMP1 2106/4885MMP2 1029/4885MMP3 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.